CN109939118A - 金雀异黄酮磷酸酯衍生物制备的组合物的用途 - Google Patents

金雀异黄酮磷酸酯衍生物制备的组合物的用途 Download PDF

Info

Publication number
CN109939118A
CN109939118A CN201811447365.3A CN201811447365A CN109939118A CN 109939118 A CN109939118 A CN 109939118A CN 201811447365 A CN201811447365 A CN 201811447365A CN 109939118 A CN109939118 A CN 109939118A
Authority
CN
China
Prior art keywords
composition
day
bone
genistein
phosphate derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811447365.3A
Other languages
English (en)
Chinese (zh)
Inventor
王上达
许宸
苏南维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hughes Biotechnology Co ltd
Original Assignee
Hughes Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hughes Biotechnology Co ltd filed Critical Hughes Biotechnology Co ltd
Publication of CN109939118A publication Critical patent/CN109939118A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
CN201811447365.3A 2017-12-07 2018-11-29 金雀异黄酮磷酸酯衍生物制备的组合物的用途 Pending CN109939118A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595697P 2017-12-07 2017-12-07
US62/595,697 2017-12-07

Publications (1)

Publication Number Publication Date
CN109939118A true CN109939118A (zh) 2019-06-28

Family

ID=64559585

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811447365.3A Pending CN109939118A (zh) 2017-12-07 2018-11-29 金雀异黄酮磷酸酯衍生物制备的组合物的用途

Country Status (6)

Country Link
US (1) US10881634B2 (enExample)
EP (1) EP3494973B1 (enExample)
JP (1) JP7029172B2 (enExample)
KR (1) KR102376603B1 (enExample)
CN (1) CN109939118A (enExample)
TW (1) TWI756495B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118359663A (zh) * 2024-04-26 2024-07-19 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250170154A1 (en) * 2023-11-28 2025-05-29 GreenStone Biosciences, Inc. Genistein phosphate derivatives

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902213A (zh) * 2003-11-18 2007-01-24 诺沃根研究股份有限公司 异黄酮类前药、其组合物和涉及它们的治疗方法
CN101969959A (zh) * 2007-07-31 2011-02-09 利默里克生物制药公司 磷酸化吡喃酮类似物和方法
CN102351828A (zh) * 2011-08-16 2012-02-15 李荣立 一种提取金雀异黄素的新工艺
CN102488210A (zh) * 2011-12-27 2012-06-13 西南大学 染料木素水凝胶的复合物及其制备方法
CN105381470A (zh) * 2015-11-27 2016-03-09 安佰超 一种改性染料木素及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063995A1 (en) * 1998-06-12 1999-12-16 Vyrex Corporation Isoflavone derivatives
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
TR201004464A2 (tr) * 2010-06-03 2012-11-21 B�Lg�� Mahmut Kemik erimesi için formülasyon.
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
TWI670374B (zh) * 2016-04-25 2019-09-01 國立臺灣大學 具有苯並吡喃酮類磷酸酯合成酶活性之多肽、包含編碼該多肽之核酸序列之微生物及苯並吡喃酮類磷酸酯衍生物之製備方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1902213A (zh) * 2003-11-18 2007-01-24 诺沃根研究股份有限公司 异黄酮类前药、其组合物和涉及它们的治疗方法
CN101969959A (zh) * 2007-07-31 2011-02-09 利默里克生物制药公司 磷酸化吡喃酮类似物和方法
CN102351828A (zh) * 2011-08-16 2012-02-15 李荣立 一种提取金雀异黄素的新工艺
CN102488210A (zh) * 2011-12-27 2012-06-13 西南大学 染料木素水凝胶的复合物及其制备方法
CN105381470A (zh) * 2015-11-27 2016-03-09 安佰超 一种改性染料木素及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHANG-TA WANG等: "Biotransformed product, genistein 7-O-phosphate,enhances the oral bioavailability of genistein", 《JOURNAL OF FUNCTIONAL FOODS》 *
谢雁飞: "染料木素衍生物对hFOB1.19活性及OPG/RANKL表达的影响", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118359663A (zh) * 2024-04-26 2024-07-19 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用
CN118359663B (zh) * 2024-04-26 2024-12-13 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用

Also Published As

Publication number Publication date
TWI756495B (zh) 2022-03-01
US20190175545A1 (en) 2019-06-13
EP3494973A1 (en) 2019-06-12
KR102376603B1 (ko) 2022-03-18
KR20190067695A (ko) 2019-06-17
US10881634B2 (en) 2021-01-05
JP7029172B2 (ja) 2022-03-03
TW201924691A (zh) 2019-07-01
EP3494973B1 (en) 2021-07-28
JP2019099579A (ja) 2019-06-24

Similar Documents

Publication Publication Date Title
CN1193751C (zh) 一种含有五羟黄酮衍生物活性成分的骨质疏松症治疗剂
Elmali et al. Fracture healing and bone mass in rats fed on liquid diet containing ethanol
CN108783467B (zh) 改善骨质疏松和增加骨密度的组合物及其制备方法
US10792324B2 (en) Compositions and methods for the treatment of orthopedic ailments
TWI756495B (zh) 用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法
Devareddy et al. The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats
JP6286417B2 (ja) 非定型骨粗鬆症に対する予防又は治療剤
NZ533225A (en) Pharmaceutical compositions based on azetidine derivatives
CN108904808A (zh) 一种治疗便秘的药物组合物及其应用
Khoo et al. Prosthetic Outcome, Patient Complaints, and Nutritional Effects on Elderly Patients with Magnet-Retained, Implant-Supported Overdentures-A 1-Year Report.
Høie et al. Lipid-lowering effect of 2 dosages of a soy protein supplement in hypercholesterolemia
Nakada et al. A new osteoporosis prevention supplements-diet improve bone mineral density in ovariectomized rats on micro-CT
Ma et al. Inhibitory effect of nicotine on bone regeneration in mandibular distraction osteogenesis
Lee et al. Evaluation of effectiveness and safety of natural plants extract (Estromon®) on perimenopausal women for 1 year
CN109771424B (zh) 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
JP3604710B2 (ja) 骨粗鬆症予防及び治療剤
Reichert et al. Influence of Diabetes Mellitus on the Development and Treatment of Malocclusions–A Case Report with Literature Review.
DOWNEY Thwart POST-MEAL Bloating and Indigestion
CN112891366B (zh) 一种治疗绝经后骨质疏松症的中药活性成分组方及其应用
RU2585108C1 (ru) Композиция для восстановления хрящевой и костной ткани при остеопорозе
CN109289038A (zh) 一种组合物及其制备方法和应用
JP2010275309A (ja) エルデカルシトールを含有する重症骨粗鬆症患者での非外傷性椎体骨折抑制剤
TWI794847B (zh) 用於減少代謝症候群之組合物及其應用
Malkin Effect of Subcutaneous Administration of Resveratrol on Bone Healing under Diabetic Conditions
US20180193312A1 (en) Nutraceutical composition and dosing regimen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190628